Cumberland Pharmaceuticals Q3 2026 net income swings to $77.78 million profit
CPIX•Cumberland Pharmaceuticals reported third-quarter 2026 net income of $77.78 million, including a gain from an asset divestiture, while revenue rose to $2.16 million. Its $100 million strategic transaction with Apotex closed July 1.
1. Quarterly results
Cumberland Pharmaceuticals swung to third-quarter 2026 net income of $77.78 million, including a gain from its asset divestiture. Total revenue rose to $2.16 million from a year earlier.
2. Transaction and development plans
The $100 million strategic transaction with Apotex closed July 1. The company said the transaction strengthened its balance sheet and allows greater focus on clinical development. It plans to submit an FDA application for ifetroban to treat DMD-associated cardiomyopathy; the agency granted rolling review.
